Interstitial Lung Disease Market Analysis & Forecast: 2026-2033
The Interstitial Lung Disease Market size is anticipated to grow at a CAGR of 6.8% with USD 4.5 Bn in 2026 and is expected to reach USD 7.20 Bn in 2033. The primary drivers are defined by rising prevalence of progressive fibrotic lung disorders, increasing diagnosis through HRCT and pulmonary function testing, and growing adoption of antifibrotic therapies such as nintedanib and pirfenidone. Some of the other factors include aging population, higher autoimmune disease-associated ILD cases, expanding pulmonology care networks, rising awareness programs, increasing clinical trials, better reimbursement for specialty drugs, and demand for early disease management. According to the Pulmonary Fibrosis Foundation, ILD includes over 200 diseases, with more than 250,000 Americans living with ILD and 50,000 new cases diagnosed annually.
On the basis of disease type, the idiopathic pulmonary fibrosis segment is projected to account for the largest Interstitial Lung Disease Market share of 42.5% in 2026. The segment’s growth is owing to its progressive nature, limited curative options, high reliance on specialist diagnosis, and strong clinical focus on slowing lung function decline. The U.S. FDA states that IPF is a rare, serious, progressive disease with no cure and limited treatment options, and is diagnosed most often in people aged 60 to 70 years.
In April 2026, Insilico Medicine announced the IND clearance from the CDE for its Rentosertib inhalation solution, mainly designed for targeted lung delivery in IPF. This AI-discovered therapy, following positive Phase IIa oral results, aims to improve pulmonary exposure, lower systemic side effects, and advance disease-modifying treatment options for the IPF patients.
To learn more about this report, Request Free Sample
On the basis of drug type, the anti-fibrotic medication segment lead with a major 54.4% share in 2026. The growth is owing to the established clinical role of nintedanib and pirfenidone in slowing progressive lung fibrosis. These therapies are widely prescribed in hospital and specialty-care settings because ILD treatment requires physician-led monitoring, dose adjustment, and safety evaluation.
The European Medicines Agency states that Ofev (nintedanib) is effective at slowing worsening lung function in adult patients with IPF, systemic sclerosis-associated ILD, and other progressive chronic fibrosing ILDs. The EMA also notes that Esbriet (pirfenidone) is used to treat adults with idiopathic pulmonary fibrosis.
Recent approvals are increasing competition within the anti-fibrotic medication segment. In April 2026, Cipla USA Inc. received U.S. FDA approval for generic nintedanib capsules in 100 mg and 150 mg strengths. This is expected to support wider access, increase prescription volume, and strengthen anti-fibrotic therapy adoption during the forecast period.
The U.S. Interstitial Lung Disease Market is being transformed by AI-enabled imaging tools that support earlier identification of lung scarring on CT scans. ILD diagnosis often requires high-resolution computed tomography, pulmonary function testing, multidisciplinary review, and exclusion of alternative causes. AI tools are now being used to quantify fibrosis, flag suspicious CT findings, and support the referral pathways to specialist ILD centers. This is important because diagnostic delay can reduce treatment opportunities in progressive fibrosing diseases, where earlier anti-fibrotic therapy may help slow lung function decline.
In January 2025, IMVARIA Inc. announced U.S. FDA 510(k) clearance for ScreenDx, an AI-powered tool designed to assist clinicians in assessing CT imaging data for findings compatible with interstitial lung disease. IMVARIA stated that ScreenDx is a software-only device that uses artificial intelligence to analyze CT imaging data as adjunctive information in a referral pathway. This development is expected to strengthen adoption of AI-supported ILD screening across hospitals, imaging centers, and pulmonology networks in the U.S.
AI-powered high-resolution CT quantification is emerging as a major breakthrough in the Interstitial Lung Disease Market. Traditional ILD assessment relies extensively on radiologist interpretation, pulmonologist review, lung function testing, as well as multidisciplinary diagnosis. However, fibrosis extent and subtle radiological progression can be difficult to measure consistently across the serial CT scans. AI-powered platforms help quantify fibrosis extent, disease severity, and progression more objectively, thereby improving the clinical trial endpoints, patient monitoring, and treatment decisions.
According to Brainomix, its e-Lung platform is an FDA-cleared AI-powered imaging software platform that automatically identifies and quantifies abnormalities on CT lung scans. It allows the clinicians to identify subtle deterioration across multiple timepoints. In January 2026, Brainomix announced that its e-Lung AI imaging technology was selected as a co-primary endpoint in a Boehringer Ingelheim Phase 3 pulmonary fibrosis clinical trial. This marks the first time automated quantitative HRCT imaging biomarkers would serve as a co-primary endpoint in a Phase 3 ILD study.
|
Current Event |
Description and its Impact |
|
2026 U.S. Medicare Part D Redesign and Ofev Price Negotiation Pressure |
|
|
FDA Approval of New PDE4B Therapy Expands Regulated ILD Treatment Options
|
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region accounts for 43% of the market share in 2026. The region’s growth is owing to the advanced pulmonology networks, strong access to HRCT imaging, FDA-approved ILD therapies, higher diagnosis rates, and a strong clinical trial ecosystem. The U.S. remains the core market due to early regulatory approvals and rapid adoption of specialty drugs.
The CDC MMWR reported 67,843 IPF deaths among U.S. workers in 2022, thereby highlighting the public-health relevance of IPF mortality and occupational exposure assessment.
In September 2025, AllRock Bio announced a $50 million Series A funding round to advance its lead pan-ROCK inhibitor, ROC-101, into Phase 2a clinical development. The program targets pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (ILD-PH), addressing a major unmet need in cardiopulmonary and fibrotic diseases.
Asia Pacificis expected to witness strong growth in Interstitial Lung Disease Market over the forecast period. The region’s growth is owing to the rising diagnosis in China, India, and Japan, expanding access to anti-fibrotic drugs, increasing specialist pulmonology centers, and improving regulatory pathways for novel therapies.
A PLOS One study estimated India’s crude annual ILD incidence at 10.1–20.2 per 100,000 and prevalence at 49.0–98.1 per 100,000 in the studied region. These trends support higher APAC growth through diagnosis, specialist care, and drug access.
In January 2025, Asian Hospital and Medical Center launched the Interstitial Lung Disease (ILD) Center under its Asian Institute of Respirology. The initiative, supported by Boehringer Ingelheim Philippines, aims to improve multidisciplinary diagnosis and management of ILD and enhance specialized respiratory care in the country.
The United States Interstitial Lung Disease Market is driven by the early FDA approvals, high use of specialty pharmacies, and strong clinical research. The country has advanced hospital infrastructure, with the American Hospital Association reporting 6,100 U.S. hospitals in 2026.
Recent innovation is reshaping the U.S. treatment landscape. In September 2025, Boehringer Ingelheim announced the U.S. FDA approval of JASCAYD (nerandomilast), the first new treatment option for idiopathic pulmonary fibrosis (IPF) in over a decade. The oral therapy targets IPF, a progressive interstitial lung disease, and works by slowing lung function decline through a novel antifibrotic and immunomodulatory mechanism.
Japan is expected to be a key Asia Pacific growth contributor due to its older population, strong specialty-care infrastructure, and early access to innovative pulmonary fibrosis therapies. The WHO notes that in Japan, around 30% of the population is already over 60 years old, which is highly relevant because IPF is most often diagnosed in older adults.
In May 2026, Boehringer Ingelheim announced that Japan’s MHLW approved Jascayd (nerandomilast) for adults with IPF and PPF. The company stated that the approval enables access to the first oral PDE4B inhibitor with anti-fibrotic and immunomodulatory effects authorized for these indications.
Some of the major key players in Interstitial Lung Disease Market are MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd, Inc., and Cipla.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.8% | 2033 Value Projection: | USD 7.20 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd, Inc., and Cipla. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
